Abstract: ObjectiveTo evaluate the effect of Huishengkoufuye on treatment and blood coagulation state in patients with Mid-advanced non-small cell lung cancer (NSCLC) after chemotherapy. MethodsSixty-nine untreated patients confirmed by pathological examination were randomly divided into two groups. Thirty-five patients in experimental group received the third generation platinum-based chemotherapy as first-line treatment(GEM+DDP or TXT+DDP)combined with Huishengkoufuye (10ml every time,third-daily).Thirty-four patients in control group received chemotherapy only. Treatment was repeated every 21 days. The objective curative effect of the two groups were compared after two cycles at least. The PLT, D-dimer and Fib were determined pre and post treatment. ResultsIn the experimental group and the control group: The overall response rates were 74.3 %( 26/35) and 47.1 %( 16/34) respectively. The CBR rates were 80.0 %( 28/35) and 55.9 %( 20/34) respectively. The TTP were(5.5±2.8)months and (4.2±2.5)respectively. The mean survival time were (11.1±5.8)months and (8.4±5.3)months respectively. The experimental group was superior to the control group in the overall response rate, CBR, TTP and mean survival time, with significant differences(P<0.05).The PLT, D-dimer and Fib after treatment were (157±89)×109/L,(2078±770) μg/ml,(3.8±1.4)g/L and (208±118)×109/L,( 2680±980) μg/ml,( 4.6±1.8) g/L respectively(P<0.05,P<0.01,P<0.05). Moreover, 3 (8.8%) patients occurred deep venous thrombosis(DVT) in the control group, but no case in the experimental group . Conclusion These results suggest that Huishengkoufuye combined with chemotherapy can enhance the treatment effect and improve blood hypercoagulable state with prevent deep venous thrombosis, which is helpful to receive a high clinical benefit response, extend TTP and mean survival time.